Bangladesh, Jan. 28 -- A revolutionary personalized cancer vaccine developed by Russias Gamaleya Research Institute of Epidemiology and Microbiology is expected to receive regulatory approval by August, potentially allowing treatments to commence as early as September, according to the institutes director, Alexander Gintsburg. This breakthrough marks a significant milestone in the global fight against cancer, leveraging advanced mRNA technology and artificial intelligence to tailor treatments for individual patients.

The Gamaleya Research Institute, renowned for its development of Sputnik V-the worlds first registered Covid-19 vaccine-has adapted mRNA technology, initially employed for combating infectious diseases, to the realm of oncol...